Annals of Oncology Advance Access originally published online on March 17, 2008
Annals of Oncology 2008 19(7):1327-1330; doi:10.1093/annonc/mdn045
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
hematologic malignancies |
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
1 Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College and New York Presbyterian Hospital
2 Department of Pathology and Laboratory Medicine, Weill Cornell Medical College
3 Division of Biostatistics and Epidemiology, Department of Public Health, Weill Cornell Medical College and New York Presbyterian Hospital, New York, USA
* Correspondence to: Dr J. P. Leonard, Starr Building Room 340, Weill Cornell Medical College and New York Presbyterian Hospital, 520 East 70th Street, New York, NY 10021, USA. Tel: +1-212-746-2932; Fax: +1-212-746-3844; E-mail: jpleonar{at}med.cornell.edu
Background: Reported median overall survival (OS) in patients with mantle cell lymphoma (MCL) has been reported to be just 3–4 years. As a consequence, first-line treatment has become more aggressive. Single-center studies with R-Hyper-CVAD and/or autologous stem-cell transplant (ASCT) have produced 3-year OS rates >80%, prompting many to adopt their use. We evaluated outcomes from a single-center cohort managed in a more traditional fashion.
Methods: We identified patients with MCL evaluated at Weill Cornell Medical Center since 1997, and included those with known date of diagnosis. An online social security database was used to verify survival.
Results: We identified 181 patients with MCL, and date of diagnosis could be determined in 111. Three-year OS from diagnosis was 86% [95% confidence interval (CI) 78% to 92%]. Median OS was 7.1 years (95% CI 63–98 months). Adequate information on therapy was available for 75 patients. Only five were treated upfront with (R)-Hyper-CVAD or ASCT while an additional four patients received one of these regimens subsequently. Treatment type had no significant effect on OS.
Conclusion: Outcomes with standard approaches can yield similar survival to that achieved with more intensive approaches. Biases may account for the perceived superiority of aggressive strategies.
Key words: chemotherapy, hyper-CVAD, mantle cell lymphoma, stem-cell transplant
Received for publication November 28, 2007. Revision received January 25, 2008. Accepted for publication January 31, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Ghielmini and E. Zucca How I treat mantle cell lymphoma Blood, August 20, 2009; 114(8): 1469 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Tam, R. Bassett, C. Ledesma, M. Korbling, A. Alousi, C. Hosing, P. Kebraei, R. Harrell, G. Rondon, S. A. Giralt, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma Blood, April 30, 2009; 113(18): 4144 - 4152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Martin, M. Coleman, and J. P. Leonard Progress in Mantle-Cell Lymphoma J. Clin. Oncol., February 1, 2009; 27(4): 481 - 483. [Full Text] [PDF]
|
|